Digest Réseau Comment ça marche
Réseau
/
Sociétés
Zy
Non vérifié

Zymeworks Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieÉtablissements Publics/Vente au DétailFinanceMédecine Santé Bien-être

38 communiqués de presse

Voir tous les communiqués de presse
18/03/2026
Biotechnologie
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
Source
Zymeworks Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
17/03/2026
Biotechnologie
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
Source
Zymeworks Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
02/03/2026
Biotechnologie
Finance
Médecine Santé Bien-être
Management/Organisation d'Entreprise
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Source
Zymeworks Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
27/01/2026
Biotechnologie
Zymeworks Announces Participation in Upcoming Investor Conferences
Source
Zymeworks Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
12/01/2026
Biotechnologie
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
Source
Zymeworks Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
11/01/2026
Biotechnologie
Médecine Santé Bien-être
Établissements Publics/Vente au Détail
Annonces Économiques
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Source
Zymeworks Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
06/01/2026
Biotechnologie
Médecine Santé Bien-être
Annonces Économiques
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Source
Zymeworks Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotechnologie
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Source
Zymeworks Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotechnologie
Annonces Économiques
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
Source
Zymeworks Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
17/11/2025
Biotechnologie
Médecine Santé Bien-être
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Source
Zymeworks Inc.
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0